Tech Company Financing Transactions
Atox Bio Funding Round
On 7/24/2014, Atox Bio secured $23 million in investment from SR One Capital Management and private investors.
Transaction Overview
Company Name
Announced On
7/24/2014
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Undisclosed
Investors
SR One Capital Management (Lead Investor) (Matthew Foy)
Proceeds Purpose
The funds will enable Atox Bio to initiate a late stage clinical study of AB103, for the treatment of necrotizing soft tissue infections (NSTI), commonly referred to as the "flesh eating bacteria" and other severe infections.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Vilcom Ctr. Dr. 230
Chapel Hill, NC 27514
USA
Chapel Hill, NC 27514
USA
Phone
Website
Email Address
Not Recorded
Overview
Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by a deregulated inflammatory response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Teleman
Chief Financial Officer
Esti Hayun
Chief Medical Officer
Wayne Dankner
Chief Scientific Officer
Raymond Kaempfer
Vice President
Corinne Zollmann
VP - Bus. Development
Robert Greif
VP - R & D
Anat Shirvan
VP - Regulatory Affairs
Meir Batito
Browse more venture capital transactions:
Prev: 7/24/2014: FreshBooks venture capital transaction
Next: 7/24/2014: NextNav Holdings venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs